| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥183.0B | ¥170.6B | +7.2% |
| Operating Income | ¥25.3B | ¥34.4B | -26.3% |
| Ordinary Income | ¥24.3B | ¥34.3B | -29.0% |
| Net Income | ¥16.9B | ¥23.8B | -25.7% |
| ROE | 8.3% | 12.8% | - |
FY2026 Q3 results showed revenue of 183.0B yen (YoY +7.2%), while operating income declined significantly to 25.3B yen (YoY -26.3%). Ordinary income decreased to 24.3B yen (YoY -29.0%) and net income fell to 16.9B yen (YoY -29.1%). Despite maintaining a high gross margin of 77.6%, the company experienced substantial profit compression due to increased selling, general, and administrative expenses. Operating cash flow turned negative at -0.5B yen, raising concerns about earnings quality and cash conversion capability. The balance sheet remains solid with total assets of 258.3B yen and equity of 202.6B yen, though short-term borrowings increased substantially by 20.0B yen to 36.0B yen. Inventory rose 30.2% to 18.4B yen, resulting in elevated inventory turnover days of 164. The company maintains its full-year forecast of 260.0B yen revenue (YoY +14.2%) but expects operating income of 3.8B yen (YoY -8.0%), indicating continued margin pressure.
[Profitability] ROE of 8.3% reflects net profit margin of 9.2%, asset turnover of 0.708, and financial leverage of 1.28x in DuPont decomposition. Operating margin declined to 13.8%, down from prior year levels, while gross margin remained strong at 77.6%. The margin compression stems primarily from increased SG&A expenses that outpaced revenue growth of 7.2%. [Cash Quality] Cash and deposits stood at 96.4B yen, providing coverage of 2.68x against short-term borrowings of 36.0B yen. Operating cash flow of -0.5B yen produced an OCF-to-net-income ratio of -0.03x, indicating weak cash conversion and earnings quality concerns. Free cash flow was negative at -13.3B yen, driven by investing activities of -8.5B yen and negative operating cash flow. [Investment Efficiency] Asset turnover of 0.708 reflects adequate capital utilization. Inventory turnover deteriorated to 164 days, up substantially from prior periods, suggesting working capital inefficiency. Receivables turnover remained moderate. Capital expenditure of 2.2B yen exceeded depreciation by 1.68x, indicating ongoing growth investment. [Financial Health] Equity ratio of 78.4% demonstrates strong capital adequacy. Current ratio of 408.6% and quick ratio of 374.6% indicate robust short-term liquidity. Debt-to-equity ratio of 0.18 and debt-to-EBITDA of 1.35x reflect conservative leverage. However, short-term debt concentration reached 100% of interest-bearing debt, creating refinancing considerations despite ample cash reserves.
Cash and deposits increased 47.4B yen YoY to 96.4B yen, supported by short-term borrowing expansion of 20.0B yen. Operating cash flow turned negative at -0.5B yen despite net income of 16.9B yen, reflecting working capital build including inventory increase of 3.3B yen and other working capital movements. The negative cash conversion ratio of -0.03x indicates earnings are not translating into cash generation. Investing cash flow of -8.5B yen consisted primarily of capital expenditures of 2.2B yen and investments in securities and subsidiaries totaling approximately 6.3B yen. Financing activities reflected dividend payments of approximately 14.7B yen offset by the 20.0B yen increase in short-term borrowings, resulting in net positive financing cash flow. Free cash flow of -13.3B yen indicates the company required external funding to support operations, investments, and dividends. The substantial cash position of 96.4B yen provides 2.68x coverage of short-term liabilities, maintaining adequate liquidity buffer despite negative operating cash flow. Working capital stood at 167.1B yen but efficiency declined due to inventory accumulation, with days inventory outstanding reaching 164 days.
Ordinary income of 24.3B yen compared to operating income of 25.3B yen shows a non-operating net loss of approximately 1.0B yen. Non-operating items included financial expenses and other costs that slightly offset operating performance. The non-operating impact represents 0.5% of revenue, a relatively minor contribution. Interest expenses of 0.2B yen resulted in an interest coverage ratio of 117x, indicating limited financial burden. However, operating cash flow of -0.5B yen falling below net income of 16.9B yen raises significant earnings quality concerns. The negative OCF-to-net-income ratio of -0.03x suggests substantial accruals or working capital deterioration undermining reported profits. The 30.2% increase in inventory to 18.4B yen and elevated inventory days of 164 indicate potential overstatement of earnings through inventory buildup or inadequate provisions. With operating cash flow unable to support reported earnings, the sustainability of profit levels warrants close monitoring until cash conversion improves.
Working Capital Efficiency Risk: Inventory increased 30.2% to 18.4B yen with inventory turnover extending to 164 days, significantly above industry norms. This accumulation ties up capital and creates exposure to obsolescence, price markdowns, and demand fluctuations. The inability to convert inventory to cash constrains liquidity and operating cash flow generation.
Operating Leverage and Margin Pressure: Despite 7.2% revenue growth, operating income fell 26.3% due to SG&A expense growth outpacing sales. Operating margin compression from prior year levels to 13.8% indicates deteriorating cost control. If revenue growth slows while fixed costs remain elevated, profitability could decline further.
Dividend Sustainability Risk: The calculated dividend payout ratio of 91.1% combined with negative free cash flow of -13.3B yen raises concerns about dividend coverage. Current dividend policy of 39.0 yen per share requires cash deployment exceeding earnings generation, necessitating either improved cash flow or potential dividend adjustment to maintain financial flexibility.
[Industry Position] (Reference - Proprietary Analysis) Profitability: ROE 8.3% aligns with industry median of 8.2% (2025-Q3, IT & Telecom sector). The company's net profit margin of 9.2% exceeds the industry median of 5.6%, ranking in the upper half of peers and reflecting strong pricing power or value-added services. Operating margin of 13.8% also surpasses the industry median of 8.0%, indicating superior operational efficiency at the gross profit level despite recent SG&A pressure. Financial Health: Equity ratio of 78.4% substantially exceeds the industry median of 59.5%, positioning the company in the top quartile for capital strength and financial stability. Current ratio of 408.6% far exceeds the industry median of 2.13x, demonstrating exceptional liquidity management. Efficiency: Asset turnover of 0.708 compares favorably to the industry median of 0.68, indicating slightly better capital utilization. However, inventory turnover days of 164 significantly exceed the industry median of 13.17 days, ranking among the weakest in the sector and highlighting material working capital inefficiency. Revenue growth of 7.2% trails the industry median of 10.5%, suggesting slower top-line momentum relative to peers. The company's Rule of 40 metric (revenue growth plus operating margin) of approximately 21% falls below the industry median of 20% but remains within acceptable range given the margin profile. ※ Industry: IT & Telecom (99 companies), Comparison: FY2025-Q3, Source: Proprietary analysis
Margin Preservation Challenge Under Revenue Growth: The company achieved 7.2% revenue growth while maintaining an exceptionally high gross margin of 77.6%, indicating strong product or service differentiation. However, the 26.3% decline in operating income reveals that SG&A expense growth outpaced sales expansion, compressing operating margin to 13.8%. This pattern suggests either growth investment spending (sales personnel, marketing, R&D) or operational inefficiency. Management's ability to leverage fixed costs as revenue scales toward the full-year target of 260.0B yen will be critical. The full-year operating income forecast of 3.8B yen implies sequential improvement from Q3 levels is expected, requiring either revenue acceleration or expense discipline in Q4.
Working Capital Management Requires Urgent Attention: The 30.2% increase in inventory to 18.4B yen and inventory days of 164 significantly exceed industry norms of 13 days, creating both operational and financial risks. This inventory buildup, combined with negative operating cash flow of -0.5B yen, indicates either demand forecasting challenges, production inefficiencies, or strategic stockpiling. The company's OCF-to-net-income ratio of -0.03x ranks poorly against the industry median cash conversion ratio of 1.40x, suggesting earnings quality deterioration. Reducing inventory levels and improving receivables collection would release substantial working capital, enabling positive free cash flow generation without external funding.
Capital Allocation Under Scrutiny Despite Strong Balance Sheet: The company maintains robust financial health with 78.4% equity ratio and 96.4B yen cash position, well above industry medians. However, the combination of 91.1% dividend payout ratio, negative FCF of -13.3B yen, and 8.5B yen in ongoing investments creates tension between shareholder returns and growth funding. The 20.0B yen increase in short-term borrowings effectively financed dividends and investments that operating cash flow could not support. While current liquidity remains ample at 2.68x short-term debt coverage, sustaining this capital allocation without improved cash generation would gradually erode financial flexibility. Management faces a strategic choice between maintaining high dividends, funding growth investments, or prioritizing operational cash flow improvement through working capital optimization.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.